Expert Ratings
Easily search Stocks, Mutual Funds, eBooks, Articles and Videos
Track the companies of Group.
| Sales Growth | Profit Growth | Expense Growth | Stock Price CAGR |
|---|---|---|---|
Presentation & Earning Calls |
Annual Reports |
Credit Rating |
|---|---|---|
|
|
|
|
The company was originally incorporated as ‘Jet Chemicals Private Limited,’ under the provisions of the Companies Act, 1956, at Mumbai, pursuant to a certificate of incorporation dated December 7, 1968, issued by the Registrar of Companies, Maharashtra at Mumbai. Pursuant to the company’s Shareholders’ resolution dated December 28, 2020, the name of the company was changed to ‘Blue Jet Healthcare Private Limited’, and a fresh certificate of incorporation dated December 30, 2020, was issued by the Registrar of Companies, Maharashtra at Mumbai. Subsequently, the company was converted into a public limited company, and pursuant to a special resolution of its Shareholders dated May 5, 2022, and the name of the company was changed to ‘Blue Jet Healthcare Limited’ A fresh certificate of incorporation was issued by Registrar of Companies, Maharashtra, at Mumbai on May 18, 2022.
The company is a speciality pharmaceutical and healthcare ingredients and intermediates company, offering niche products targeted toward innovator pharmaceutical companies and multi-national generic pharmaceutical companies. Since its incorporation in 1968, it has established a contract development and manufacturing organization (CDMO) business model with specialized chemistry capabilities in contrast media intermediates and high intensity sweeteners, on the back of strategic and early investments in research and development (R&D) and manufacturing infrastructure. It has competencies and manufacturing capabilities in contrast media intermediates and high-intensity sweeteners, including saccharin and its salts. The company manufactures a range of products in-house, including the key starting intermediate and advanced intermediates, which allows it to control its production process for consistent quality and cost effectiveness.
The company has built a long-term customer base with innovator pharmaceutical companies and multi-national generic pharmaceutical companies, supported by committed multi-year contracts of up to five years. The company’s ‘Collaboration, Development, Manufacturing’ approach has been, and will continue to be, critical to its success and a key factor for growing its CDMO business. Its product capabilities across the pharmaceutical and healthcare categories have evolved with its customers’ needs, supported by its manufacturing capabilities and technology-driven product development. Its operations are primarily organized in three product categories: (i) contrast media intermediates, (ii) high intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (APIs).
Business area of the company
The company is a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API.
Key awards, accreditations or recognitions
Major events and milestones
Comment